|
JPS5144499B1
(enExample)
|
1970-08-29 |
1976-11-29 |
|
|
|
JPS5824836B2
(ja)
|
1974-10-14 |
1983-05-24 |
ノウミボウサイコウギヨウ カブシキガイシヤ |
カサイナドノツウホウソウチ
|
|
US4769320A
(en)
|
1982-07-27 |
1988-09-06 |
New England Medical Center Hospitals, Inc. |
Immunoassay means and methods useful in human native prothrombin and human abnormal prothorombin determinations
|
|
CA1209907A
(en)
|
1982-04-12 |
1986-08-19 |
Richard M. Bartholomew |
Method of affinity purification employing monoclonal antibodies
|
|
US4689299A
(en)
|
1982-09-30 |
1987-08-25 |
University Of Rochester |
Human monoclonal antibodies against bacterial toxins
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4737456A
(en)
|
1985-05-09 |
1988-04-12 |
Syntex (U.S.A.) Inc. |
Reducing interference in ligand-receptor binding assays
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
JPS6350741A
(ja)
|
1986-08-20 |
1988-03-03 |
Nippon Tectron Co Ltd |
蛍光偏光分析装置
|
|
JPH06104071B2
(ja)
|
1986-08-24 |
1994-12-21 |
財団法人化学及血清療法研究所 |
第▲ｉｘ▼因子コンホメ−シヨン特異性モノクロ−ナル抗体
|
|
US4801687A
(en)
|
1986-10-27 |
1989-01-31 |
Bioprobe International, Inc. |
Monoclonal antibody purification process using protein A
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5004697A
(en)
|
1987-08-17 |
1991-04-02 |
Univ. Of Ca |
Cationized antibodies for delivery through the blood-brain barrier
|
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
|
US5322678A
(en)
|
1988-02-17 |
1994-06-21 |
Neorx Corporation |
Alteration of pharmacokinetics of proteins by charge modification
|
|
DE68913658T3
(de)
|
1988-11-11 |
2005-07-21 |
Stratagene, La Jolla |
Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
CA2006684C
(en)
|
1988-12-30 |
1996-12-17 |
Charles T. Esmon |
Monoclonal antibody against protein c
|
|
US5202253A
(en)
|
1988-12-30 |
1993-04-13 |
Oklahoma Medical Research Foundation |
Monoclonal antibody specific for protein C and antibody purification method
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
|
JPH0636741B2
(ja)
|
1989-11-08 |
1994-05-18 |
帝人株式会社 |
ヒト・プロテインｃの分離方法
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
DE69130561T2
(de)
|
1990-02-16 |
1999-06-24 |
Boston Biomedical Research Institute, Inc., Boston, Mass. |
Hybride Reagenzien mit der Fähigkeit, Moleküle selektiv in Zellen freizusetzen
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
CA2095633C
(en)
|
1990-12-03 |
2003-02-04 |
Lisa J. Garrard |
Enrichment method for variant proteins with altered binding properties
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
KR100249937B1
(ko)
|
1991-04-25 |
2000-04-01 |
나가야마 오사무 |
인간 인터루킨-6 수용체에 대한 재구성 인간 항체
|
|
JP4124480B2
(ja)
|
1991-06-14 |
2008-07-23 |
ジェネンテック・インコーポレーテッド |
免疫グロブリン変異体
|
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
|
EP0604580A1
(en)
|
1991-09-19 |
1994-07-06 |
Genentech, Inc. |
EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
|
AU675929B2
(en)
|
1992-02-06 |
1997-02-27 |
Curis, Inc. |
Biosynthetic binding protein for cancer marker
|
|
GB9203459D0
(en)
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
EP0669836B1
(en)
|
1992-11-13 |
1996-07-03 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
|
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
|
DE69434689D1
(de)
|
1993-06-10 |
2006-05-18 |
Genetic Therapy Inc |
Adenovirale vektoren für die behandlung der hämophilie
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
IL107742A0
(en)
|
1993-11-24 |
1994-02-27 |
Yeda Res & Dev |
Chemically-modified binding proteins
|
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
|
US6309636B1
(en)
|
1995-09-14 |
2001-10-30 |
Cancer Research Institute Of Contra Costa |
Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
|
|
ATE552012T1
(de)
|
1994-10-07 |
2012-04-15 |
Chugai Pharmaceutical Co Ltd |
Hemmung des abnormalen wachstums von synovialzellen durch il-6-antagonisten als wirkstoff
|
|
DE4436561C1
(de)
|
1994-10-13 |
1996-03-14 |
Deutsche Spezialglas Ag |
Verfahren zur Veränderung der Durchbiegung von anodisch gebondeten flächigen Verbundkörpern aus Glas und Metall oder Halbleitermaterialien
|
|
HU225392B1
(en)
|
1994-10-21 |
2006-11-28 |
Chugai Pharmaceutical Co Ltd |
Use of an antibody againts interleukin-6-receptor for producing a pharmaceutical composition for treating anemia and cachexia caused by il-6 production
|
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
|
US6485943B2
(en)
|
1995-01-17 |
2002-11-26 |
The University Of Chicago |
Method for altering antibody light chain interactions
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
|
US5830478A
(en)
|
1995-06-07 |
1998-11-03 |
Boston Biomedical Research Institute |
Method for delivering functional domains of diphtheria toxin to a cellular target
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
US5783186A
(en)
|
1995-12-05 |
1998-07-21 |
Amgen Inc. |
Antibody-induced apoptosis
|
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
|
NZ333650A
(en)
|
1996-07-19 |
2000-02-28 |
Amgen Inc |
Analogs of cationic proteins like NT-3 (neurotrophin-3) and BDNF (brain derived neurotrophic factor) that are circulated more readily due to a lower isoelectric point and a lower protein charge relative to the native protein
|
|
US5990286A
(en)
|
1996-12-18 |
1999-11-23 |
Techniclone, Inc. |
Antibodies with reduced net positive charge
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
US20070059302A1
(en)
|
1997-04-07 |
2007-03-15 |
Genentech, Inc. |
Anti-vegf antibodies
|
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
WO1998046257A1
(en)
|
1997-04-17 |
1998-10-22 |
Amgen Inc. |
Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
|
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
|
ES2244066T3
(es)
|
1997-06-24 |
2005-12-01 |
Genentech, Inc. |
Procedimiento y composiciones de glicoproteinas galactosiladas.
|
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
|
WO1999018212A1
(fr)
|
1997-10-03 |
1999-04-15 |
Chugai Seiyaku Kabushiki Kaisha |
Anticorps humain naturel
|
|
EP1028751B1
(en)
|
1997-10-31 |
2008-12-31 |
Genentech, Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
|
PT1034298E
(pt)
|
1997-12-05 |
2012-02-03 |
Scripps Research Inst |
Humanização de anticorpo murino
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
DE69937291T2
(de)
|
1998-04-02 |
2008-07-10 |
Genentech, Inc., South San Francisco |
Antikörpervarianten und fragmente davon
|
|
PT1069185E
(pt)
|
1998-04-03 |
2011-08-11 |
Chugai Pharmaceutical Co Ltd |
Anticorpo humanizado contra factor tecidual (tf) humano e processo para construção de um anticorpo humanizado
|
|
PT2180007E
(pt)
|
1998-04-20 |
2013-11-25 |
Roche Glycart Ag |
Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
EP1105427A2
(en)
|
1998-08-17 |
2001-06-13 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
|
US6475718B2
(en)
|
1998-09-08 |
2002-11-05 |
Schering Aktiengesellschaft |
Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
|
|
JP2002531466A
(ja)
|
1998-12-01 |
2002-09-24 |
プロテイン デザイン ラブス， インコーポレイテッド |
γ−インターフェロンに対するヒト化抗体
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
KR20060067983A
(ko)
|
1999-01-15 |
2006-06-20 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
|
US6972125B2
(en)
|
1999-02-12 |
2005-12-06 |
Genetics Institute, Llc |
Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
|
|
EP2275540B1
(en)
|
1999-04-09 |
2016-03-23 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
|
JP2003512821A
(ja)
|
1999-10-04 |
2003-04-08 |
メディカゴ インコーポレイテッド |
外来性遺伝子の転写調節方法
|
|
JP4668498B2
(ja)
|
1999-10-19 |
2011-04-13 |
協和発酵キリン株式会社 |
ポリペプチドの製造方法
|
|
SE9903895D0
(sv)
|
1999-10-28 |
1999-10-28 |
Active Biotech Ab |
Novel compounds
|
|
EP1240319A1
(en)
|
1999-12-15 |
2002-09-18 |
Genentech, Inc. |
Shotgun scanning, a combinatorial method for mapping functional protein epitopes
|
|
NZ518764A
(en)
|
1999-12-29 |
2004-02-27 |
Immunogen Inc |
Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
|
|
AU4761601A
(en)
|
2000-04-11 |
2001-10-23 |
Genentech Inc |
Multivalent antibodies and uses therefor
|
|
US20020034537A1
(en)
|
2000-05-03 |
2002-03-21 |
Brita Schulze |
Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
|
|
MXPA02012434A
(es)
|
2000-06-16 |
2004-09-06 |
Cambridge Antibody Tech |
Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii.
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
|
KR100877676B1
(ko)
|
2000-10-06 |
2009-01-09 |
교와 핫꼬 기린 가부시키가이샤 |
항체 조성물을 생산하는 세포
|
|
ES2333775T3
(es)
|
2000-10-10 |
2010-03-01 |
Genentech, Inc. |
Inhibicion de la activacion del complemento c5 para el tratamiento y la prevencion de rechazo de xenoinjerto retrasado o rechazo vascular agudo.
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
ATE378403T1
(de)
|
2000-11-30 |
2007-11-15 |
Medarex Inc |
Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
|
|
EP2357187A1
(en)
|
2000-12-12 |
2011-08-17 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
|
JP4303475B2
(ja)
|
2001-04-13 |
2009-07-29 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
Ｖｌａ−１に対する抗体
|
|
US7667004B2
(en)
|
2001-04-17 |
2010-02-23 |
Abmaxis, Inc. |
Humanized antibodies against vascular endothelial growth factor
|
|
KR100877176B1
(ko)
|
2001-06-22 |
2009-01-07 |
츄가이 세이야꾸 가부시키가이샤 |
항글리피칸 3항체를 포함하는 세포증식 억제제
|
|
US20040161741A1
(en)
|
2001-06-30 |
2004-08-19 |
Elazar Rabani |
Novel compositions and processes for analyte detection, quantification and amplification
|
|
NZ603111A
(en)
|
2001-08-03 |
2014-05-30 |
Roche Glycart Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
|
MXPA04001301A
(es)
|
2001-08-17 |
2004-07-08 |
Tanox Inc |
Inhibidores de la ruta del complemento que se unen a c5 y c5a son evitar la formacion de c5b.
|
|
US20030049203A1
(en)
|
2001-08-31 |
2003-03-13 |
Elmaleh David R. |
Targeted nucleic acid constructs and uses related thereto
|
|
US7320789B2
(en)
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
|
EP1443961B1
(en)
|
2001-10-25 |
2009-05-06 |
Genentech, Inc. |
Glycoprotein compositions
|
|
IL161968A0
(en)
|
2001-11-14 |
2005-11-20 |
Centocor Inc |
Anti-il-6 antibodies, compositions, methods and uses
|
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
|
US6684637B2
(en)
|
2002-01-25 |
2004-02-03 |
Sunpower, Inc. |
Parallel slot heat exchanger
|
|
WO2003068801A2
(en)
|
2002-02-11 |
2003-08-21 |
Genentech, Inc. |
Antibody variants with faster antigen association rates
|
|
AR038568A1
(es)
|
2002-02-20 |
2005-01-19 |
Hoffmann La Roche |
Anticuerpos anti-a beta y su uso
|
|
AU2003217912A1
(en)
*
|
2002-03-01 |
2003-09-16 |
Xencor |
Antibody optimization
|
|
US20040259150A1
(en)
|
2002-04-09 |
2004-12-23 |
Kyowa Hakko Kogyo Co., Ltd. |
Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
|
|
WO2003085118A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for producing antibody composition
|
|
WO2003084570A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
|
|
US7691568B2
(en)
|
2002-04-09 |
2010-04-06 |
Kyowa Hakko Kirin Co., Ltd |
Antibody composition-containing medicament
|
|
EP1500698B1
(en)
|
2002-04-09 |
2011-03-30 |
Kyowa Hakko Kirin Co., Ltd. |
Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
|
|
EA200401325A1
(ru)
|
2002-04-09 |
2005-04-28 |
Киова Хакко Когио Ко., Лтд. |
Клетки с модифицированным геномом
|
|
EP1513879B1
(en)
|
2002-06-03 |
2018-08-22 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
|
EP1512015B1
(en)
|
2002-06-12 |
2009-03-25 |
Genencor International, Inc. |
Methods for improving a binding characteristic of a molecule
|
|
CA2488836A1
(en)
|
2002-06-12 |
2003-12-24 |
Genencor International, Inc. |
Methods and compositions for milieu-dependent binding of a targeted agent to a target
|
|
ITMI20021527A1
(it)
|
2002-07-11 |
2004-01-12 |
Consiglio Nazionale Ricerche |
Anticorpi anti componente c5 del complemento e loro uso
|
|
WO2004016740A2
(en)
|
2002-08-15 |
2004-02-26 |
Epitomics, Inc. |
Humanized rabbit antibodies
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
RS20100366A
(sr)
|
2002-12-16 |
2011-04-30 |
Genentech, Inc. |
Varijante imunoglobulina i njihova upotreba
|
|
US20050079574A1
(en)
|
2003-01-16 |
2005-04-14 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
|
JP2006517109A
(ja)
|
2003-02-07 |
2006-07-20 |
プロテイン デザイン ラブス インコーポレイテッド |
アンフィレグリン抗体ならびに癌および乾癬を処置するためのその使用
|
|
PT1601697E
(pt)
|
2003-02-28 |
2007-09-04 |
Lonza Biologics Plc |
Purificação de anticorpos através de proteína a e cromatografia de troca iónica.
|
|
AU2004268497A1
(en)
|
2003-02-28 |
2005-03-10 |
Antigenics Inc. |
Use of lectins to promote oligomerization of glycoproteins and antigenic molecules
|
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
|
ES2538469T3
(es)
|
2003-06-05 |
2015-06-22 |
Genentech, Inc. |
Terapia de combinación para trastornos de células B
|
|
JP2007504245A
(ja)
|
2003-09-05 |
2007-03-01 |
ジェネンテック・インコーポレーテッド |
変更したエフェクター機能を有する抗体
|
|
US20080241884A1
(en)
|
2003-10-08 |
2008-10-02 |
Kenya Shitara |
Fused Protein Composition
|
|
WO2005035778A1
(ja)
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
α1,6-フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
|
|
WO2005035753A1
(ja)
|
2003-10-10 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
機能蛋白質を代替する二重特異性抗体
|
|
ME01775B
(me)
|
2003-11-05 |
2011-02-28 |
Glycart Biotechnology Ag |
Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
|
|
PT1689777E
(pt)
|
2003-11-05 |
2007-05-31 |
Ares Trading Sa |
Processo para a purificação da proteína de ligação a il-18
|
|
CN103394083B
(zh)
|
2003-11-06 |
2017-07-18 |
西雅图基因公司 |
能够与配体偶联的单甲基缬氨酸化合物
|
|
EP1697415A1
(en)
|
2003-11-12 |
2006-09-06 |
Biogen Idec MA Inc. |
NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
|
|
JPWO2005053742A1
(ja)
|
2003-12-04 |
2007-06-28 |
協和醗酵工業株式会社 |
抗体組成物を含有する医薬
|
|
CN1889978A
(zh)
|
2003-12-10 |
2007-01-03 |
米德列斯公司 |
干扰素α抗体及其用途
|
|
ZA200605825B
(en)
|
2004-01-09 |
2007-11-28 |
Pfizer |
Antibodies to madcam
|
|
US20050169921A1
(en)
|
2004-02-03 |
2005-08-04 |
Leonard Bell |
Method of treating hemolytic disease
|
|
US20070116710A1
(en)
|
2004-02-03 |
2007-05-24 |
Leonard Bell |
Methods of treating hemolytic anemia
|
|
WO2005080429A2
(en)
|
2004-02-11 |
2005-09-01 |
Warner-Lambert Company Llc |
Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies
|
|
WO2005092925A2
(en)
|
2004-03-24 |
2005-10-06 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
|
US20050260711A1
(en)
|
2004-03-30 |
2005-11-24 |
Deepshikha Datta |
Modulating pH-sensitive binding using non-natural amino acids
|
|
WO2005097832A2
(en)
|
2004-03-31 |
2005-10-20 |
Genentech, Inc. |
Humanized anti-tgf-beta antibodies
|
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
|
EP2360186B1
(en)
|
2004-04-13 |
2017-08-30 |
F. Hoffmann-La Roche AG |
Anti-P-selectin antibodies
|
|
WO2005112564A2
(en)
|
2004-04-15 |
2005-12-01 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Germline and sequence variants of humanized antibodies and methods of making and using them
|
|
KR100620554B1
(ko)
|
2004-06-05 |
2006-09-06 |
한국생명공학연구원 |
Ｔａｇ-72에 대한 인간화 항체
|
|
AR049390A1
(es)
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
Anticuerpos contra la interleuquina-13 humana y usos de los mismos
|
|
NZ551335A
(en)
|
2004-06-18 |
2010-03-26 |
Ambrx Inc |
Antibodies and fragments thereof comprising an non naturally encoded amino acid coupled to a linker
|
|
WO2006004663A2
(en)
|
2004-06-25 |
2006-01-12 |
Medimmune, Inc. |
Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
|
|
PL2471813T3
(pl)
|
2004-07-15 |
2015-09-30 |
Xencor Inc |
Zoptymalizowane warianty Fc
|
|
EP1776384B1
(en)
|
2004-08-04 |
2013-06-05 |
Mentrik Biotech, LLC |
Variant fc regions
|
|
CA2579142A1
(en)
|
2004-09-13 |
2006-03-23 |
Macrogenics, Inc. |
Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof
|
|
AU2005284006A1
(en)
|
2004-09-14 |
2006-03-23 |
Health Protection Agency |
Vaccine
|
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ｏｘ４０ｌ抗體
|
|
CN104447992A
(zh)
|
2004-09-23 |
2015-03-25 |
健泰科生物技术公司 |
半胱氨酸改造的抗体和偶联物
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
US7462697B2
(en)
|
2004-11-08 |
2008-12-09 |
Epitomics, Inc. |
Methods for antibody engineering
|
|
US20070135620A1
(en)
|
2004-11-12 |
2007-06-14 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
EP2208783A1
(en)
|
2004-12-22 |
2010-07-21 |
Chugai Seiyaku Kabushiki Kaisha |
Method of producing an antibody using a cell in which the function of fucose transporter is inhibited
|
|
JP2008525327A
(ja)
|
2004-12-23 |
2008-07-17 |
ノヴォ ノルディスク アクティーゼルスカブ |
抗体結合親和性リガンド
|
|
GB0502358D0
(en)
|
2005-02-04 |
2005-03-16 |
Novartis Ag |
Organic compounds
|
|
US10011858B2
(en)
|
2005-03-31 |
2018-07-03 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
|
EP1876236B9
(en)
|
2005-04-08 |
2015-02-25 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody substituting for function of blood coagulation factor viii
|
|
WO2006121852A2
(en)
|
2005-05-05 |
2006-11-16 |
Duke University |
Anti-cd19 antibody therapy for autoimmune disease
|
|
ES2534760T3
(es)
|
2005-08-19 |
2015-04-28 |
Wyeth Llc |
Anticuerpos antagonistas contra GDF-8 y sus usos en el tratamiento de ELA y otros trastornos asociados con GDF-8
|
|
EP1957531B1
(en)
|
2005-11-07 |
2016-04-13 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
|
|
WO2007060411A1
(en)
|
2005-11-24 |
2007-05-31 |
Ucb Pharma S.A. |
Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
|
|
EP1959997A4
(en)
|
2005-11-28 |
2009-12-23 |
Medimmune Llc |
ANTAGONISTS OF HMGB1 AND / OR RAGE AND METHOD OF USE THEREOF
|
|
WO2007064919A2
(en)
|
2005-12-02 |
2007-06-07 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
|
ES2551604T3
(es)
|
2005-12-12 |
2015-11-20 |
Ac Immune S.A. |
Vacuna terapéutica
|
|
ES2807928T3
(es)
|
2005-12-29 |
2021-02-24 |
Janssen Biotech Inc |
Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos
|
|
SG171578A1
(en)
|
2006-03-02 |
2011-06-29 |
Alexion Pharma Inc |
Prolongation of survival of an allograft by inhibiting complement activity
|
|
SG10201706440RA
(en)
|
2006-03-08 |
2017-09-28 |
Archemix Llc |
Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
|
|
BR122017024057B8
(pt)
|
2006-03-15 |
2021-05-25 |
Alexion Pharma Inc |
anticorpo que se liga à c5 e composição farmacêutica compreendendo dito anticorpo e um veículo farmaceuticamente aceitável
|
|
EP3345616A1
(en)
|
2006-03-31 |
2018-07-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
|
EP2006381B1
(en)
|
2006-03-31 |
2016-02-03 |
Chugai Seiyaku Kabushiki Kaisha |
Method for controlling blood pharmacokinetics of antibodies
|
|
KR20140071452A
(ko)
|
2006-04-05 |
2014-06-11 |
애브비 바이오테크놀로지 리미티드 |
항체 정제
|
|
US20070292936A1
(en)
|
2006-05-09 |
2007-12-20 |
Genentech, Inc. |
Binding polypeptides with optimized scaffolds
|
|
DK2047863T3
(da)
|
2006-06-08 |
2013-09-16 |
Chugai Pharmaceutical Co Ltd |
Middel til forebyggelse eller behandling af inflammatoriske sygdomme
|
|
US10118970B2
(en)
|
2006-08-30 |
2018-11-06 |
Genentech, Inc. |
Multispecific antibodies
|
|
AU2007319576B2
(en)
|
2006-10-06 |
2014-01-16 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Prevention of tissue ischemia, related methods and compositions
|
|
US20100034194A1
(en)
|
2006-10-11 |
2010-02-11 |
Siemens Communications Inc. |
Eliminating unreachable subscribers in voice-over-ip networks
|
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
|
US20100166748A1
(en)
|
2007-03-22 |
2010-07-01 |
Novartis Ag |
C5 Antigens and Uses Thereof
|
|
CN100592373C
(zh)
|
2007-05-25 |
2010-02-24 |
群康科技(深圳)有限公司 |
液晶显示面板驱动装置及其驱动方法
|
|
CN101796408B
(zh)
|
2007-06-29 |
2014-05-07 |
奎斯特诊断投资公司 |
用液相层析-质谱法分析体液内的氨基酸
|
|
TWI578998B
(zh)
|
2007-09-26 |
2017-04-21 |
中外製藥股份有限公司 |
抗ｉｌ－６受體的抗體
|
|
ES2595638T3
(es)
|
2007-09-26 |
2017-01-02 |
Chugai Seiyaku Kabushiki Kaisha |
Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
|
|
CA3139492C
(en)
|
2007-09-26 |
2024-04-30 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant region
|
|
RU2010116756A
(ru)
|
2007-09-28 |
2011-11-10 |
Чугаи Сейяку Кабусики Кайся (Jp) |
Антитело против глипикана-3 с улучшенными кинетическими показателями в плазме
|
|
US8414893B2
(en)
|
2007-12-21 |
2013-04-09 |
Amgen Inc. |
Anti-amyloid antibodies and uses thereof
|
|
SI2235064T1
(sl)
|
2008-01-07 |
2016-04-29 |
Amgen Inc. |
Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
|
|
EP3056513A1
(en)
|
2008-04-11 |
2016-08-17 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
|
CA2722600C
(en)
|
2008-05-01 |
2014-01-21 |
Amgen Inc. |
Anti-hepcidin antibodies and methods of use
|
|
AU2009257370B2
(en)
|
2008-06-14 |
2015-01-22 |
Auris Health, Inc. |
System and method for delivering energy to tissue
|
|
EP2328616B1
(en)
|
2008-08-05 |
2015-04-29 |
Novartis AG |
Compositions and methods for antibodies against complement protein c5
|
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
|
FI2894165T3
(fi)
|
2008-11-10 |
2023-03-23 |
Alexion Pharma Inc |
Menetelmiä ja koostumuksia komplementtiin liityvien häiriöiden hoitamiseksi
|
|
WO2010098863A1
(en)
|
2009-02-26 |
2010-09-02 |
Lpath, Inc. |
Humanized platelet activating factor antibody design using anti-lipid antibody templates
|
|
WO2010151526A1
(en)
|
2009-06-23 |
2010-12-29 |
Alexion Pharmaceuticals, Inc. |
Bispecific antibodies that bind to complement proteins
|
|
CN101875696B
(zh)
*
|
2009-11-11 |
2012-02-08 |
中国人民解放军军事医学科学院生物工程研究所 |
一种抗体及其制备方法与应用
|
|
EP2327725A1
(en)
|
2009-11-26 |
2011-06-01 |
InflaRx GmbH |
Anti-C5a binding moieties with high blocking activity
|
|
WO2011094593A2
(en)
|
2010-01-28 |
2011-08-04 |
Ab Biosciences, Inc. |
Novel lowered affinity antibodies and methods of marking the same
|
|
WO2011109338A1
(en)
*
|
2010-03-01 |
2011-09-09 |
Alexion Pharmaceuticals Inc. |
Methods and compositions for treating degos' disease
|
|
TW201206466A
(en)
*
|
2010-03-11 |
2012-02-16 |
Rinat Neuroscience Corp |
Antibodies with pH dependent antigen binding
|
|
SG10201507722QA
(en)
|
2010-03-11 |
2015-10-29 |
Rinat Neuroscience Corp |
ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
|
|
TWI667257B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
|
|
SG185107A1
(en)
|
2010-04-30 |
2012-12-28 |
Alexion Pharma Inc |
Antibodies having reduced immunogenicity in a human
|
|
TWI761912B
(zh)
|
2010-11-30 |
2022-04-21 |
日商中外製藥股份有限公司 |
具有鈣依存性的抗原結合能力之抗體
|
|
CA2822288A1
(en)
|
2010-12-22 |
2012-06-28 |
Medimmune, Llc |
Anti-c5/c5a/c5adesr antibodies and fragments
|
|
SG10201609665PA
(en)
|
2011-02-25 |
2017-01-27 |
Chugai Pharmaceutical Co Ltd |
FcɣRIIb-SPECIFIC Fc ANTIBODY
|
|
SI2714733T1
(sl)
|
2011-05-21 |
2019-06-28 |
Macrogenics, Inc. |
CD3-vezavne molekule sposobne vezave na humani ali ne-humani CD3
|
|
WO2012177653A2
(en)
*
|
2011-06-20 |
2012-12-27 |
St. Louis University |
Targeting the neuromuscular junction for treatment
|
|
EP2762493B1
(en)
|
2011-09-30 |
2021-06-09 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
|
|
TW201817744A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
|
|
EP3617313A1
(en)
|
2011-10-05 |
2020-03-04 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for promoting clearance from plasma of antigen comprising saccharide chain receptor-binding domain
|
|
EP2787081A4
(en)
|
2011-11-30 |
2015-10-07 |
Chugai Pharmaceutical Co Ltd |
PHARMACEUTICAL CARRIER IN CELLS FOR THE FORMATION OF AN IMMUNOMOPLEX
|
|
KR102219987B1
(ko)
|
2012-02-24 |
2021-02-25 |
추가이 세이야쿠 가부시키가이샤 |
ＦｃγＲＩＩＢ를 매개로 항원의 소실을 촉진하는 항원 결합 분자
|
|
PT2825036T
(pt)
|
2012-03-16 |
2018-07-26 |
Regeneron Pharma |
Anticorpos de cadeia leve manipulados em histidina e roedores geneticamente modificados para gerar os mesmos
|
|
NZ629077A
(en)
|
2012-03-16 |
2015-12-24 |
Regeneron Pharma |
Non-human animals expressing ph-sensitive immunoglobulin sequences
|
|
DK2831117T3
(en)
*
|
2012-03-29 |
2017-12-18 |
Novimmune Sa |
ANTI-TLR4 ANTIBODIES AND APPLICATIONS THEREOF
|
|
TWI619729B
(zh)
*
|
2012-04-02 |
2018-04-01 |
再生元醫藥公司 |
抗－ｈｌａ－ｂ*２７抗體及其用途
|
|
JPWO2013180201A1
(ja)
|
2012-05-30 |
2016-01-21 |
中外製薬株式会社 |
会合化した抗原を消失させる抗原結合分子
|
|
JP6309521B2
(ja)
|
2012-08-13 |
2018-04-11 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
ｐＨ依存性結合特性を有する抗ＰＣＳＫ９抗体
|
|
US9133269B2
(en)
|
2012-08-24 |
2015-09-15 |
Anaptysbio, Inc. |
Humanized antibodies directed against complement protein C5
|
|
TW201418707A
(zh)
*
|
2012-09-21 |
2014-05-16 |
Alexion Pharma Inc |
補體組分ｃ５拮抗劑之篩選分析
|
|
US10280215B2
(en)
|
2013-01-31 |
2019-05-07 |
Seoul National University R&Db Foundation |
Anti-C5 antibodies and methods of treating complement-related diseases
|
|
US9701743B2
(en)
|
2014-02-20 |
2017-07-11 |
Allergan, Inc. |
Complement component C5 antibodies
|
|
US9321686B2
(en)
|
2013-03-15 |
2016-04-26 |
Forta Corporation |
Reinforcement fiber coating compositions, methods of making and treating, and uses for improved adhesion to asphalt and portland cement concrete
|
|
EP2968985A2
(en)
|
2013-03-15 |
2016-01-20 |
Amgen, Inc. |
Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
|
|
US20160051673A1
(en)
|
2013-03-29 |
2016-02-25 |
Alexion Pharmaceuticals, Inc. |
Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
|
|
TWI636062B
(zh)
|
2013-04-02 |
2018-09-21 |
中外製藥股份有限公司 |
Fc region variant
|
|
CA2920293A1
(en)
|
2013-08-16 |
2015-02-19 |
Alexion Pharmaceuticals, Inc. |
Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
|
|
JP6382641B2
(ja)
|
2013-09-11 |
2018-08-29 |
株式会社東芝 |
非水電解質電池及び非水電解質電池の製造方法
|
|
NZ631007A
(en)
|
2014-03-07 |
2015-10-30 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
|
JP2016024424A
(ja)
|
2014-07-24 |
2016-02-08 |
株式会社リコー |
情報処理システム、情報処理装置、情報処理方法、及びプログラム
|
|
UA128712C2
(uk)
|
2014-12-19 |
2024-10-09 |
Чугаі Сейяку Кабусікі Кайся |
Антитіла проти c5 та способи застосування
|
|
CN107428823B
(zh)
|
2015-01-22 |
2021-10-26 |
中外制药株式会社 |
两种以上抗-c5抗体的组合与使用方法
|
|
CN112142844B
(zh)
|
2015-02-05 |
2025-07-25 |
中外制药株式会社 |
包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
|
|
KR20180095740A
(ko)
|
2015-02-27 |
2018-08-27 |
추가이 세이야쿠 가부시키가이샤 |
Il-6 관련 질환 치료용 조성물
|
|
EP3277715A2
(en)
|
2015-03-31 |
2018-02-07 |
Alexion Pharmaceuticals, Inc. |
Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patients
|
|
US20180311299A1
(en)
|
2015-05-01 |
2018-11-01 |
Alexion Pharmaceuticals, Inc. |
Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
|
|
WO2016209956A1
(en)
|
2015-06-26 |
2016-12-29 |
Alexion Pharmaceuticals, Inc. |
A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
|
|
TW201718014A
(zh)
|
2015-10-12 |
2017-06-01 |
諾華公司 |
C5抑制劑於移植相關微血管病之用途
|
|
FI3390442T3
(fi)
|
2015-12-18 |
2023-11-10 |
Chugai Pharmaceutical Co Ltd |
Anti-C5-vasta-aineita ja käyttömenetelmiä
|
|
US10233252B2
(en)
|
2015-12-21 |
2019-03-19 |
Wisconsin Alumni Research Foundation |
pH-dependent antibodies targeting the transferrin receptor and methods of use thereof to deliver a therapeutic agent
|
|
WO2017123636A1
(en)
|
2016-01-11 |
2017-07-20 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment
|
|
EP3408291A1
(en)
|
2016-01-25 |
2018-12-05 |
Shire Human Genetic Therapies, Inc. |
Anti-c5 antibodies with enhanced ph switch
|
|
MY191668A
(en)
|
2016-06-14 |
2022-07-06 |
Regeneron Pharma |
Anti-c5 antibodies and uses thereof
|
|
TWI807666B
(zh)
|
2016-06-17 |
2023-07-01 |
日商中外製藥股份有限公司 |
抗c5抗體及使用方法
|
|
KR20230043247A
(ko)
|
2017-01-31 |
2023-03-30 |
추가이 세이야쿠 가부시키가이샤 |
C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
|
|
CA3054067A1
(en)
|
2017-03-14 |
2018-09-20 |
Five Prime Therapeutics, Inc. |
Antibodies binding to vista at acidic ph
|
|
AU2018235031B2
(en)
|
2017-03-16 |
2021-08-12 |
Medimmune Limited |
Anti-PAR2 antibodies and uses thereof
|
|
JP7486415B2
(ja)
|
2017-04-03 |
2024-05-17 |
インフラルクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
Ｃ５ａ活性のインヒビターでの炎症性疾患の処置
|
|
AU2018354404B2
(en)
|
2017-10-26 |
2025-10-30 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-C5 antibodies for treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS)
|
|
MX2020005547A
(es)
|
2017-12-04 |
2020-08-20 |
Ra Pharmaceuticals Inc |
Moduladores de la actividad del complemento.
|
|
US20210301004A1
(en)
|
2018-08-01 |
2021-09-30 |
Chugai Seiyaku Kabushiki Kaisha |
A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
|